Skip to main content


Julia Winter is the new CEO of Transbiomed, a spin-off of the Vall d'Hebron Research Institute (VHIR) in Barcelona that has recently developed a urine test for early diagnosis of prostate cancer.

Born in Colorado (United States), Winter has roughly 20 years of experience in the field of scientific innovation and business. Highlights of her resume include her proven ability to manage, create strategies and develop business, in addition to her in-depth knowledge of the international biotechnology market.

She has been on the board of directors at ERA Biotech, in charge of identifying new biotech investment opportunities in Spain for Sofinnova Partners, head of business development at ALZA Corp., junior partner at venture capital firm InterWest Partners in Palo Alto (California), and an analyst at Furman Selz, Inc. in New York.

Transbiomed was founded in 2007 by doctors Jaume Reventós, Andreas Doll and Miguel Abal from the Vall d’Hebron University Hospital and Raimon Forés, executive in the biotechnology sector. Last February they closed a round of funding valued at €1.2 millions with venture capital firm Inveready Seed Capital.

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.